The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 00400/0005R.
Malarivon Syrup 50mg in 5ml (as base) Oral Solution
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
1. What is Malarivon Syrup and what is it used for?
2. What you need to know before you use Malarivon Syrup?
3. How to use Malarivon Syrup?
4. Possible side effects?
5. How to store Malarivon Syrup?
6. Contents of the pack and other information.
Malarivon Syrup contains chloroquine phosphate and belongs to a group of medicines called ‘anti-malarials’. It acts on the malarial parasite in the blood stream, and may prevent, suppress or treat the disease depending upon the strain of parasite contracted and the progression of the disease.
You must get medical advice on which anti-malarial medicine to take.
When travelling to an area where there is a risk of contracting malaria always consult official guidelines and local information before deciding on which preventative treatment to take. No treatment to prevent malaria is 100% effective.
Talk to your doctor or pharmacist before taking Malarivon Syrup if:
Long term treatment with Malarivon Syrup should be under medical supervision and your doctor will monitor your eyesight and perform blood tests for you. If you experience any visual disturbances other than a temporary inability to focus at the start of treatment then stop taking the medicine immediately and seek the advice of your doctor.
Taking Malarivon Syrup can result in severe reductions of blood sugar levels. In extreme cases this may result in loss of consciousness. If you notice symptoms that may be related to low blood sugar levels such as shakiness, heart palpitations, poor muscle coordination, pins & needles, slurred speech, dizziness and/or light headedness then consult your doctor.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Tell your doctor or pharmacist if you are taking any of the following medicines. This is because Malarivon Syrup may affect the amount of these medicines in your blood:
Also tell your doctor or pharmacist if you are taking any of the following medicines:
Antacids and adsorbents used to treat heartburn or indigestion can interfere with the absorption of chloroquine so they should not be taken within four hours before or after taking Malarivon Syrup.
Malarivon Syrup can make the symptoms of ‘myasthenia gravis’ (which causes muscle weakness) more severe and as a consequence reduce the effectiveness of drugs such as neostigmine and pyridostigmine used to treat the condition.
When Malarivon Syrup is taken at the same time as rabies vaccination it may affect the protection provided by the vaccine.
Malarivon Syrup inactivates oral typhoid vaccine, so the vaccine should be taken at least three days before starting a course of Malarivon Syrup.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
There are risks to both the mother and the foetus associated with travelling to countries with malaria when pregnant. Always consult a doctor or pharmacist before travelling.
Breast feeding while taking Malarivon Syrup is safe but the small amount of the active ingredient expressed in the milk is not enough to protect the infant from malaria. Therefore, your baby will still need to be given anti-malarial medicines. Ask your doctor or pharmacist who will be able to give you advice.
When starting treatment with Malarivon Syrup it is possible that you may have blurred or double vision which will make driving and operating machinery unsafe. If you experience such effects then do not drive or operate machinery.
In addition to the active ingredient, some of the other ingredients in Malarivon Syrup may affect some individuals:
Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Read these instructions carefully because the dose depends both on age and the reason for treatment.
Age Group Dose
Children up to 1 year 2.5ml to 5.0ml
1 to 3 years 7.5ml to 10ml
3 to 6 years 10ml to 15ml
6 to 9 years 15ml to 22.5ml
9 to 12 years 22.5ml to 30ml
Over 12 years including adults 30ml
In the following directions, unless you have been told by a doctor that you are partially immune to malaria, assume that you are non-immune and select the appropriate dose.
Suppression or prevention of malaria in non-immune users
Take one dose a week as shown in Table 1. Begin two weeks before entering the malaria area and continue for four weeks after leaving the malaria area.
Suppression or prevention of malaria in partially immune users
Once every two weeks take half the dose shown in Table 1. This will afford a high degree of protection against non-resistant malaria.
Treatment of malaria in non-immune users
Firstly take twice the dose in Table 1. Then, six hours later, take the dose as stated in Table 1. Then, for the next two days, take the dose as stated in Table 1.
Treatment of malaria in partially immune users
Once only, take twice the dose in Table 1.
If you have taken a possible overdose then you should seek medical advice immediately. If possible you should take any remaining medicine, packaging and this leaflet with you provided it doesn’t cause a delay.
Do not take a double dose to make up for a forgotten dose. If a dose is missed then resume the treatment immediately. If the product was being taken for prevention of Malaria then be especially alert for any flu like symptoms in the months following and report them immediately to your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Common (affects 1 to 10 people in a 100 people):
Uncommon (affects 1 to 10 people in a 1,000):
Rare (affects less than 1 in 1000 people):
Frequency not known:
Very Common (affects more than 1 in 10 people):
Common (affects 1 to 10 people in a 100):
Uncommon (affects 1 to 10 people in a 1,000):
Rare (affects less than 1 in a 1000 people):
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the bottle.
Store below 25°C. Protect from light.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is chloroquine phosphate. Each 5ml of the syrup contains 80mg of chloroquine phosphate which is equivalent to 50mg of chloroquine base. The other ingredients are sucrose, methyl, ethyl, propyl and butyl parahydroxybenzoates, propylene glycol, buttermint toffee essence, sodium saccharin, glycerol, ponceau 4R (E124) and purified water.
Malarivon Syrup is a clear red syrup supplied in glass bottles of 75ml.
The marketing authorisation owner is:
The manufacturer is:
This leaflet was last revised in September 2015